Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

By S. Zeuzem, G. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R. Hyland, A. Illeperuma, E. Svarovskaia, D. Brainard, W. Symonds and 7 more. New England Journal of Medicine, 2014

877 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Immunology

View Paper: https://www.semanticscholar.org/paper/2ffaea2dc21c53cdbb5e46591d5274f990c8030e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Ghany
2. D. Nelson
3. E. Lawitz
4. Kristen M. Marks
5. D. Wyles
6. Timothy R. Morgan
7. J. Lalezari
8. Kris V. Kowdley

Citations in the corpus

• EASL Recommendations on Treatment of Hepatitis C 2015. (2015, neutral): “In the VALENCE trial [51], the SVR rates after 24 weeks of treatment were 94% (86/92) in treatment-naïve non-cirrhotic individuals, 92% (12/13) in treatment-naïve cirrhotics, 87% (87/ 100) in treatment-experienced non-cirrhotic patients, and 60% (27/45) in treatment-experienced cirrhotic patients.”
• Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, methodology): “(286) The use of sofosbuvir plus ribavirin is further supported by clinical trial data involving adolescents(287) and adults with genotype 2 or 3 infection.(288-291) At the time of manuscript preparation, sofosbuvir (plus ribavirin) remained the only FDA-approved DAA for children 3-11 years with gen”
• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015, neutral): “Irritability 4 (3) 9 (7) 23 (8) 40 (15)”
• All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study (2015, methodology): “In addition, there was an increased incidence of anemia, which is consistent with the hemolytic anemia known to occur with RBV treatment.(15,16) Thus, patients with genotype 3 infection have a need for improved treatment options, preferably with therapies of shorter duration and without the addition”